HWHong Wang

Hong Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hong Wang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ZNF598 enhances FAT10-mediated non-covalent stabilization of Tat to promote HIV-1 transcription and replication

    by Hongyun Shi, Panpan Quan, Chaohui Tang, Yubao Hou, Huihan Wang, Yingchao Wang, Hong Wang, Wenyan Zhang


  • Open Access

    TRIP12 promotes HIV-1 replication and latency reactivation by stabilizing Tat via USP7-mediated deubiquitination

    by Hongyun Shi, Panpan Quan, Yubao Hou, Huihan Wang, Yingchao Wang, Hong Wang, Wenyan Zhang

    HIV-1 Tat functions as a key transcriptional activator that amplifies viral transcription by recruiting host transcription elongation machinery, thereby forming a self-amplifying positive-feedback loop. Thus, cellular levels and post-translational modifications of Tat directly determine the efficiency of viral replication, as well as the establishment and reactivation of proviral latency. Elucidating the regulatory network that maintains Tat protein levels is therefore important for developing HIV cure strategies. Here, we identify the E3 ubiquitin ligase TRIP12 as a novel positive regulator of Tat stability that inhibits its proteasomal degradation. TRIP12 stabilizes Tat independently of its intrinsic E3 ligase activity by enhancing the interaction between the deubiquitinase USP7 and Tat, thereby reducing K48-linked ubiquitination of Tat, a modification typically associated with protein degradation. TRIP12 knockout significantly accelerates Tat degradation due to reduced USP7-Tat interaction, resulting in the suppression of viral transcription and impaired reactivation of latent virus. Moreover, TRIP12-mediated stabilization of Tat is consistently observed among multiple clade B HIV-1 strains tested in this study. Notably, TRIP12 mRNA levels are associated with plasma viral load and disease progression in people living with HIV, suggesting a potential clinical relevance of TRIP12 in HIV-1 pathogenesis. These findings expand our understanding of host-virus interactions and provide new insights into the molecular regulation of Tat stability, offering a potential basis for developing Tat-targeted therapeutic strategies. IMPORTANCE: HIV-1 Tat is essential for viral transcription and the establishment of latency and reactivation and represents a potential target for achieving a functional cure of acquired immunodeficiency syndrome (AIDS). In this study, we identify the host E3 ubiquitin ligase TRIP12 as a positive regulator that enhances USP7-mediated K48-linked deubiquitination of Tat, thereby stabilizing Tat protein. The TRIP12-USP7-Tat regulatory axis promotes HIV-1 replication and reactivation of latent HIV-1. This work uncovers a previously unrecognized mechanism by which the host ubiquitin system regulates Tat homeostasis and highlights potential therapeutic avenues for modulating HIV-1 latency.


  • Open Access

    Research progress on HIV-1 structural proteins and antiviral therapies

    by Huihan Wang, Jinsong Yuan, Hong Wang

    Human Immunodeficiency Virus (HIV), including HIV-1 and HIV-2, is a retrovirus that causes Acquired Immunodeficiency Syndrome (AIDS). HIV primarily targets the human immune system, especially CD4 + T lymphocytes, leading to progressive immune system dysfunction and rendering patients susceptible to severe opportunistic infections and malignancies. HIV-1 accounts for the majority of global HIV infections, and most structural, mechanistic, and therapeutic studies have been conducted in HIV-1 systems. The structural proteins Gag, Pol, and Env of HIV-1 play a pivotal role in the viral life cycle, making their functional mechanisms and inhibitor development key to advancing anti-AIDS drug research. This article provides a narrative review of recent advances in antiviral drug development targeting these proteins and discusses future design strategies. It offers critical insights for accelerating next-generation anti-HIV drug development and advancing global AIDS control efforts.


  • Open Access

    A novel FITC.Chimeric antigen receptor-T cell targeting HIV-1-infected cells with FITC-conjugated antibodies for enhanced cytotoxicity

    by Zhizhong Mi, Junjian Chen, Chen Huan, Baisong Zheng, Weijing Yang, Kai Deng, Jiacong Zhao, Jinghe Huang, Hong Wang, Na Du, et al.


  • Open Access

    HERC5-mediated ISGylation of SARS-CoV-2 nsp8 facilitates its degradation and inhibits viral replication

    by Yubao Hou, Hongyun Shi, Huihan Wang, Li Tian, Chen Huan, Yan Liu, Hong Wang, Wenyan Zhang


  • Open Access

    FBXO45 restricts HIV-1 replication by inducing SQSTM1/p62-mediated autophagic degradation of Tat

    by Mingxiu Xu, Haobo Hu, Weijing Yang, Jiaxiang Zhang, Hong Wang, Wenyan Zhang, Chen Huan

    As a key regulator of human immunodeficiency virus type 1 (HIV-1) transcription, Tat plays an essential role in viral replication and latency, making it a promising target for designing viral control strategies. Identifying host factors that modulate Tat and exploring the underlying mechanisms will benefit our understanding of HIV-1 transcriptional regulation and provide valuable insights into Tat-based therapeutic strategies. Here, by employing the TurboID approach, we discovered high-affinity binding between FBXO45 and Tat. Our findings demonstrate that FBXO45 negatively regulates Tat by promoting Tat ubiquitination and directing it to autophagic degradation. Autophagic degradation of Tat has been reported, but the specific underlying mechanisms remain unidentified. We elucidated this issue by providing evidence that FBXO45-mediated Tat polyubiquitination is an essential prerequisite for this process. Silencing of FBXO45 leads to a deficiency of autophagy receptor SQSTM1/p62 to bind and facilitate the autophagic degradation of Tat. Our results further underscore the crosstalk between post-translational modifications of Tat by demonstrating that the phosphorylation site of the Tat S62 residue is required for ubiquitination induced by FBXO45. Furthermore, in the context of the regulation of HIV-1, FBXO45 inhibits viral replication and maintains the latency of HIV-1 by suppressing viral transcription. Importantly, FBXO45 overexpression significantly attenuated viral rebound after antiretroviral therapy withdrawal. In summary, our findings suggest a novel role for FBXO45 in regulating HIV-1 replication by inducing the ubiquitination and SQSTM1/p62-dependent autophagic degradation of Tat. Considering the indispensable role of Tat in the regulation of HIV-1 replication and reactivation, FBXO45 may be a potential target for therapeutic intervention against HIV-1. IMPORTANCE: HIV-1 Tat plays an indispensable role in regulating viral transcription and is a promising target for achieving a functional cure for AIDS. Identifying the host factors that modulate Tat expression could benefit the development of anti-HIV-1 strategies targeting Tat. Using TurboID assay, we identified a significant interaction between FBXO45 and Tat. Functionally, FBXO45 ubiquitinates and directs Tat for SQSTM1/p62-mediated autophagic degradation, thereby effectively restricting HIV-1 replication and maintaining HIV-1 latency by suppressing Tat-dependent viral transcription. These findings uncover a novel role for FBXO45 in regulating Tat and broaden our understanding of the host mechanisms involved in Tat processing.


  • Open Access

    LncRNA NKILA inhibits HBV replication by repressing NF-κB signalling activation

    by Xi Zhang, Yuanyuan Li, Chen Huan, Yubao Hou, Rujia Liu, Hongyun Shi, Peng Zhang, Baisong Zheng, Yingchao Wang, Hong Wang, et al.

    Hepatitis B virus (HBV) infection results in liver cirrhosis and hepatocellular carcinoma (HCC). HBx/nuclear factor (NF)-κB pathway plays a role in HBV replication. However, whether NF-κB-interacting long noncoding RNA (NKILA), a suppressor of NF-κB activation, regulates HBV replication remains largely unknown. In this study, gain-and-loss experiments showed that NKILA inhibited HBV replication by inhibiting NF-κB activity. In turn, HBV infection down-regulated NKILA expression. In addition, expression levels of NKILA were lower in the peripheral blood-derived monocytes (PBMCs) of HBV-positive patients than in healthy individuals, which were correlated with HBV viral loads. And a negative correlation between NKILA expression level and HBV viral loads was observed in blood serum from HBV-positive patients. Lower levels of endogenous NKILA were also observed in HepG2 cells expressing a 1.3-fold HBV genome, HBV-infected HepG2-NTCP cells, stable HBV-producing HepG2.2.15 and HepAD38 ​cells, compared to those HBV-negative cells. Furthermore, HBx was required for NKILA-mediated inhibition on HBV replication. NKILA decreased HBx-induced NF-κB activation by interrupting the interaction between HBx and p65, whereas NKILA mutants lack of essential domains for NF-ĸB inhibition, lost the ability to inhibit HBV replication. Together, our data demonstrate that NKILA may serve as a suppressor of HBV replication via NF-ĸB signalling.


  • Open Access

    Requirement of HIV-1 Vif C-terminus for Vif-CBF-β interaction and assembly of CUL5-containing E3 ligase

    by Hong Wang, Guoyue Lv, Xiaohong Zhou, Zhaolong Li, Xin Liu, Xiao-Fang Yu, Wenyan Zhang

    Human immunodeficiency virus type 1 (HIV-1) Vif hijacks an E3 ligase to suppress natural APOBEC3 restriction factors, and core binding factor β (CBF-β) is required for this process. Although an extensive region of Vif spanning most of its N-terminus is known to be critical for binding with CBF-β, involvement of the Vif C-terminus in the interaction with CBF-β has not been fully investigated. Here, through immunoprecipitation analysis of Vif C-terminal truncated mutants of various lengths, we identified that CBF-β binding requires not only certain amino acids (G126A, E134A, Y135A and G138A) in the HCCH region but also the HCCH motif itself, which also affects the Vif-mediated suppression of APOBEC3G/APOBEC3F (A3G/A3F). These mutants still maintained interactions with substrate A3G or A3F as well as other cellular factors ElonginB/C (ELOB/C), indicating that their structures were not functionally affected. Moreover, by determining that the BC box also is necessary for CBF-β interaction in vivo, we speculate that binding to ELOB/C induces conformational changes in Vif, facilitating its interaction with CBF-β and consequent interaction with CUL5. These results provide important information on the assembly of the Vif-CUL5-E3 ubiquitin ligase. Identification of the new binding interface with CBF-β at the C-terminus of HIV-1 Vif also provides novel targets for the development of HIV-1 inhibitors.